Navigation Links
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Date:6/30/2008

target="_new">http://www.anesiva.com and going to the Investor Information page. A slide presentation that will accompany the call also will be available for download from the Investor Information page. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing (800) 642-1687 (international dial: (706) 645-9291) and giving the following pass code: 53907567.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
2. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
3. Anesiva Announces First Quarter 2008 Financial Results
4. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
5. Anesiva Announces Expansion of Zingo Agreement in Europe
6. Anesiva Announces New Zingo Marketing and Distribution Agreement
7. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
8. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
9. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... a new study led by George Washington University ... nucleation of ice in small droplets is strongly ... at the nanoscale. The formation of ice at ... question whose answer also has important implications for ... crystallization of ice from supercooled water is generally ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative ... Genzyme, a Sanofi company and leading biotech company, recently ... a multi-use facility in the United States. With Door ... this latest order underscores the satisfaction and success the ... device improving doorway access control. , “We recommend ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and ... announced the successful delivery and installation of a ... to a major Japanese manufacturing company. ... advanced nanoimprint lithography tool that has the ability ... sizes and types. Based on Nanonex inventions and ...
Breaking Biology Technology:Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2
... Centocor Ortho Biotech Inc. announced today that a federal ... Laboratories in a patent infringement suit. , , "We ... in the patent litigation case against Abbott," said Kim Taylor, ... relates to the company,s anti-TNF class of arthritis treatments, and ...
... , FRANKLIN LAKES, N.J., June 29 BD (Becton, ... it will conduct a live webcast of its third fiscal quarter ... a.m. (EDT). BD will issue a press release detailing the ... the conference call, along with related slides, will be accessible through ...
... BETHESDA, Md., June 29 Micromet, Inc. (Nasdaq: ... antibodies for the treatment of cancer, inflammation and autoimmune ... Russell 3000 Index as part of the annual reconstitution ... 2009. , , "Investors recognize the Russell 3000 ...
Cached Biology Technology:Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories 2Micromet Added to Russell 3000 Index 2Micromet Added to Russell 3000 Index 3Micromet Added to Russell 3000 Index 4
(Date:5/21/2013)... attached to a whale entangled in fishing gear, scientists ... a whale,s diving and swimming behavior. The monitoring revealed ... migrate, depletes their energy as they drag gear for ... death. , The scientists in this entanglement response suction-cupped ... female North Atlantic right whale called Eg 3911. The ...
(Date:5/21/2013)... class of pharmaceuticals can both prevent and treat Alzheimer,s ... "TSPO ligands," are currently used for certain types of ... ligand in young adult mice when pathology was at ... was quite severe," said lead researcher Christian Pike of ... measures of pathology and improved behavior at both ages." ...
(Date:5/21/2013)... health stores, phosphatidylserine is a natural food supplement ... improve cognition and slow memory loss, it,s a ... Now a team headed by Prof. Gil Ast ... Department of Human Molecular Genetics have ... of genes involved in degenerative brain disorders, including ...
Breaking Biology News(10 mins):Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Drugs found to both prevent and treat Alzheimer's disease in mice 2Common food supplement fights degenerative brain disorders 2
... Adam Abate showed up seven months late to his ... he was busy setting up the technology for a ... he had received as a postdoctoral scholar at Harvard ... ready to start a second company, applying the science ...
... have discovered how to extract and use information in an ... focus distance, a feat only accomplished by human and animal ... human eye has an auto-focusing system, but human auto-focusing rarely ... trial and error to focus an object. Johannes ...
... Computing Center (TACC) at the University of Texas at ... a world-class supercomputer with comprehensive computing and visualization capabilities ... by a $27.5 million grant from the National Science ... NSF "eXtreme Digital" (XD) program, an integrating system for ...
Cached Biology News:'QB3 Startup In A Box' helps UC entrepreneurs launch companies 2'QB3 Startup In A Box' helps UC entrepreneurs launch companies 3Researchers develop optimal algorithm for determining focus error in eyes and cameras 2Stampede charges computational science forward in tackling complex societal challenges 2Stampede charges computational science forward in tackling complex societal challenges 3Stampede charges computational science forward in tackling complex societal challenges 4
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
GM130 Immunogen: Recombinant purified rat GM130 Family / Subclass 1: Signal Transduction Storage: 4 C...
... clone E978 GenBank ... Immunogen : NY-ESO-1 ... mouse ascites with 0.05% ... routinely evaluated by immunoblot ...
R26.4C...
Biology Products: